Is Beryl Drugs Ltd (524606) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Beryl Drugs Ltd is a below average quality company .

Is Beryl Drugs Ltd (524606) undervalued or overvalued?

The key valuation ratios of Beryl Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Beryl Drugs Ltd (524606) share price return in the past 10 years?

Beryl Drugs Ltd share price has declined -2.4% annually (CAGR) over the past ten years.

Is Beryl Drugs Ltd (524606) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beryl Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Beryl Drugs Ltd (524606)?

Company share prices are keep on changing according to the market conditions. The current trading price of Beryl Drugs Ltd (524606) on 17-Apr-2026 16:59:59 at 16:59 is 25.46.

What is the P/E ratio of Beryl Drugs?

The latest standalone P/E ratio of Beryl Drugs as of 17-Apr-2026 is 993.27.

What is the P/B ratio of Beryl Drugs Ltd (524606)?

The latest standalone P/B ratio of Beryl Drugs Ltd (524606) as of 17-Apr-2026 is 1.39.

What is the 52-week high and low of Beryl Drugs Ltd (524606)?

The 52-week high of Beryl Drugs Ltd (524606) is Rs. 30.00 and the 52-week low is Rs. 15.92.

Beryl Drugs Ltd (524606) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Beryl Drugs Ltd (524606)
Brand: Beryl Drugs

Beryl Drugs Ltd (524606) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Beryl Drugs Ltd (524606)

BSE: 524606 NSE:

Key Metrics

Market Cap

₹13 Cr.

P/E Ratio

993.27

Price to Book (P/B)

1.39

Price to Sales (P/S)

0.73

EV/EBITDA

10.84

Return on Capital Employed (ROCE)

10.15%

Current Price

₹25.5

Return on Equity (ROE)

6.30%

Return on Assets (ROA)

3.43%

Operating Profit Margin

4.7%

Net Profit Margin

2.74%

Gross Profit Margin

10%

Book Value per Share

₹18.3

Sales Growth (YoY)

-20.88%

Sales Growth (3 Years)

13.15%

Operating Profit Growth (1 Year)

-54.55%

Operating Profit Growth (3 Years)

32.49%

Net Profit Growth (1 Year)

-24.68%

52-Week Low / High

₹16 / 30

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

27.48%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Beryl Drugs Ltd?

Beryl Drugs Ltd revenue growth is -20.9% for FY-2025 , which is below its 5 year CAGR of 10.5% , indicating slower growth.

Q.1 Promoter shareholding and pledge status of Beryl Drugs Ltd?

Promoters hold 27.48% of the Beryl Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Beryl Drugs Ltd vs industry peers?

Beryl Drugs Ltd revenue CAGR is 10.53% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Beryl Drugs Ltd belong to?

Beryl Drugs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Beryl Drugs Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -2.4% based on the current price.

DeciZen - make an informed investing decision on Beryl Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Beryl Drugs stock performance

Key Ratios

Is Beryl Drugs Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	5.6%	4.5%	16.9%	10%	4.1%	6.3%	-3.8%	11.5%	11.1%	10.2%	-
Value Creation Index ⓘ	-0.6	-0.7	0.2	-0.3	-0.7	-0.6	-1.3	-0.2	-0.2	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	13.1	11	15.1	13	12.8	14.1	14.6	26.9	26.7	21.2	18
Sales YoY Gr.	-	-16.2%	37.8%	-14.4%	-1.1%	9.9%	3.6%	84%	-0.5%	-20.9%	-
Adj EPS ⓘ	0.2	0.2	1.3	1.2	0.1	-0.2	-1.3	1.5	1.5	1.1	0
YoY Gr.	-	16.7%	528.6%	-10.6%	-92.4%	-266.7%	NA	NA	-0.7%	-24%	-
BVPS (₹) ⓘ	13.1	13.4	13.1	14.8	15	15.6	14.3	15.9	17.6	18.7	18.3
Adj Net Profit ⓘ	0.1	0.1	0.7	0.6	0.1	-0.1	-0.7	0.8	0.8	0.6	0
Cash Flow from Ops. ⓘ	-0.1	0.3	-0.1	3.4	0.2	0.3	-0.5	2.4	0.8	2.6	-
Debt/CF from Ops. ⓘ	-13.5	6.3	-14.8	1	28.3	15.1	-11.3	1.9	6.2	1.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5.5%	10.5%	13.2%	-20.9%
Adj EPS ⓘ	22.8%	66.2%	NA	-24%
BVPSⓘ	4%	4.5%	9.3%	6.6%
Share Price	-2.4%	36.1%	21.3%	12.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	1.4	1.6	10	8.4	0.6	-1	-8.6	10	9	6.3	0.2
Op. Profit Mgn % ⓘ	3.8	4.5	6.9	8	7.1	10.3	3	7.4	8.2	4.7	9
Net Profit Mgn % ⓘ	0.7	1	4.4	4.6	0.4	-0.5	-4.5	2.9	2.9	2.7	0.1
Debt to Equity ⓘ	0.3	0.3	0.2	0.4	0.7	0.7	0.7	0.6	0.6	0.4	-
Working Cap Days ⓘ	170	215	185	195	186	232	266	146	151	176	87
Cash Conv. Cycle ⓘ	104	149	114	95	72	93	114	58	76	112	37

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	0	-
TTM Sales (₹ Cr.)	17.7	-
BVPS (₹) ⓘ	18.3	-
Reserves (₹ Cr.) ⓘ	4	-
P/BV ⓘ	1.39	-
PE ⓘ	993.27	-

From the Market
52 Week Low / High (₹)	15.92 / 30.00
All Time Low / High (₹)	0.60 / 53.00
Market Cap (₹ Cr.)	12.9
Equity (₹ Cr.)	5.1
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Beryl Drugs - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	13.11	10.99	15.14	12.96	12.82	14.09	14.60	26.87	26.73	21.15
Operating Expenses ⓘ +	12.61	10.50	14.10	11.94	11.91	12.64	14.17	24.88	24.53	20.15
Manufacturing Costs	8.91	7.07	9.44	7.49	7.82	8.77	9.88	17.06	16.57	14
Material Costs	1.51	1.15	1.69	1.44	0.87	0.73	0.60	1.57	1.31	0.78
Employee Cost	1.13	0.90	0.77	0.85	0.85	1.03	1.13	1.49	1.72	2
Other Costs ⓘ	1.06	1.38	2.20	2.16	2.37	2.12	2.56	4.77	4.93	3.36
Operating Profit ⓘ	0.50	0.49	1.04	1.02	0.91	1.45	0.43	1.99	2.20	1
Operating Profit Margin (%)	3.8%	4.5%	6.9%	7.9%	7.1%	10.3%	3.0%	7.4%	8.2%	4.7%
Other Income ⓘ +	0.37	0.26	0.69	0.24	0.23	0.19	0.16	0.28	0.48	1.65
Exceptional Items ⓘ	0	0	0	0	0	0.45	0	0	0	0
Interest ⓘ	0.21	0.21	0.13	0.15	0.32	0.47	0.46	0.47	0.47	0.54
Depreciation ⓘ	0.41	0.38	0.33	0.32	0.66	1.27	1.09	0.81	1.20	1.25
Profit Before Tax ⓘ	0.25	0.17	1.27	0.80	0.16	0.35	-0.95	0.98	1.01	0.87
Tax ⓘ	0.08	0.05	0.28	0.21	0.11	0.11	-0.29	0.22	0.24	0.29
Profit After Tax	0.17	0.12	0.99	0.59	0.05	0.24	-0.66	0.77	0.77	0.58
PAT Margin (%)	1.3%	1.1%	6.6%	4.6%	0.4%	1.7%	-4.5%	2.9%	2.9%	2.7%
Adjusted EPS (₹)	0.3	0.2	2.0	1.2	0.1	0.5	-1.3	1.5	1.5	1.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	6.66	6.79	6.67	7.53	7.63	7.93	7.29	8.07	8.92	9.50
Share Capital ⓘ	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09	5.09
Reserves ⓘ	1.57	1.70	1.57	2.43	2.53	2.84	2.20	2.97	3.83	4.41
Debt +	1.68	1.69	1.46	3.05	4.71	4.34	5.29	4.54	5.09	4.07
Long Term Debt	0	0.09	0.07	1.30	2.31	1.99	1.68	2.71	2.40	1.74
Short Term Debt	1.67	1.60	1.39	1.76	2.39	2.35	3.62	1.84	2.69	2.34
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	0.74	1.16	1.45	1.79	1.80	2.22	3.06	3.25	2.02	1.12
Others Liabilities ⓘ	0.82	1.43	1.22	2.12	2.78	4.16	2	1.62	1.67	1.34
Total Liabilities ⓘ	9.91	11.07	10.80	14.49	16.91	18.65	17.65	17.48	17.71	16.03
Fixed Assets
Net Fixed Assets ⓘ +	2.44	2.26	2.04	1.67	8.34	7.33	5.86	5.81	5.96	6.01
Gross Block	8.96	9.15	2.67	2.54	9.84	10.09	9.69	10.44	11.65	12.93
Accumulated Depreciation	6.52	6.89	0.62	0.87	1.50	2.76	3.83	4.63	5.68	6.92
CWIP ⓘ	0	0	0.08	6.24	0	0	0	0	0	0
Investments ⓘ	0.68	0.68	0.39	0.77	0.82	0.12	0.16	0.15	0	0
Inventories	1.54	2.69	1.35	0.76	1.16	2.27	2.98	1.05	1.26	1.90
Trade Receivables	3.53	3.60	4.83	3.44	3.45	4.54	4.45	6.90	7.58	5.46
Cash Equivalents	0.63	0.77	0.14	0.10	0.40	0.45	0.67	0.57	0.12	0.81
Others Assets ⓘ	1.07	1.08	1.97	1.52	2.74	3.94	3.53	2.99	2.77	1.86
Total Assets ⓘ	9.91	11.07	10.80	14.49	16.91	18.65	17.65	17.48	17.71	16.03

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0.13	0.27	-0.10	3.35	0.18	0.34	-0.47	2.39	0.82	2.64
PBT ⓘ	0.27	0.17	1.27	0.80	0.16	0.35	-0.95	0.98	1.01	0.87
Adjustment ⓘ	0.66	0.40	-0.39	0.28	0.83	1.14	1.37	1.12	1.53	1.64
Changes in Working Capital ⓘ	-0.54	-0.13	-0.87	2.53	-0.66	-1.13	-0.85	0.35	-1.52	0.31
Tax Paid ⓘ	-0.16	-0.12	-0.11	-0.26	-0.15	-0.02	-0.03	-0.06	-0.20	-0.18
Cash Flow From Investing Activity ⓘ +	0.17	0.05	-0.03	-5.01	-1.55	0.26	0.52	-1.18	-1.08	-0.40
Capex	-0.20	-0.20	0.17	-0.06	-1.88	-0.24	0.40	-0.75	-1.33	-1.28
Net Investments	0	0	0.28	0	0	0.97	0	0	0.22	0
Others ⓘ	0.37	0.25	-0.48	-4.95	0.32	-0.48	0.13	-0.43	0.03	0.88
Cash Flow From Financing Activity ⓘ +	-0.23	-0.19	-0.36	1.62	1.67	-0.54	-0.24	-1.20	0.10	-1.55
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0.09	-0.02	1.39	1.35	-0.07	-0.31	1.03	-0.25	-0.66
Interest Paid ⓘ	-0.21	-0.20	-0.13	-0.15	-0.32	-0.47	-0.41	-0.44	-0.46	-0.53
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.02	-0.08	-0.21	0.37	0.64	-0	0.48	-1.80	0.81	-0.36
Net Cash Flow ⓘ	-0.19	0.13	-0.49	-0.04	0.30	0.06	-0.18	0.01	-0.16	0.69

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	2.54	1.74	14.8	8.35	0.63	3.09	-8.68	10	9.07	6.3
ROCE (%)	5.55	4.48	16.88	9.96	4.05	6.28	-3.82	11.51	11.14	10.15
Asset Turnover Ratio	1.32	1.09	1.4	1.02	0.82	0.79	0.8	1.53	1.52	1.25
PAT to CFO Conversion(x)	-0.76	2.25	-0.1	5.68	3.6	1.42	N/A	3.1	1.06	4.55
Working Capital Days
Receivable Days	97	114	100	116	98	104	112	77	99	113
Inventory Days	41	67	48	30	27	44	66	27	16	27
Payable Days	286	302	282	410	755	1,006	1,617	735	734	730

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beryl Drugs Ltd FAQs

The current trading price of Beryl Drugs on 17-Apr-2026 16:59 is ₹25.46.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Beryl Drugs stood at ₹12.91 Cr

The latest P/E ratio of Beryl Drugs as of 16-Apr-2026 is 993.3.

The latest P/B ratio of Beryl Drugs as of 16-Apr-2026 is 1.39.

The 52-week high of Beryl Drugs is ₹30.00 and the 52-week low is ₹15.92.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beryl Drugs is ₹17.66 ( Cr.) .

About Beryl Drugs Ltd

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products.

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

Small volume injectables in liquid form
Small volume injectables in dry powder form
Variety of eye and ear drops
I.V.Fluids in polypack and glass bottles
Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Beryl Drugs Ltd (524606) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Beryl Drugs Share Price